• to decreased the potential risk of critical cardiovascular (heart and blood vessel) issues in adults with variety two diabetes and cardiovascular diseaseCalifornia biotech behemoth Amgen ditched plans for an experimental weight loss tablet in May but continues to be hoping to get a slice of the marketplace with MariTide, a month to month inject